Sio Gene, Genocea, Solid Biosciences, Saniona and Black Diamond join First Wave, Zosano, Vallon, Finch, Magenta, ProQR and Imara on the growing list of biopharma firms reducing headcount to make their cash last until valuations return to a level that may support new fundraising. 

Study will examine prior authorization and other access restrictions at 15 of the largest US commercial payers for a group of 27 drugs.

Study will look at prior authorization, step therapy and required medication switching for drugs considered to be reasonably priced.

Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.